Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

20.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical Treatment for Toe Deformities in Stiff-Person Syndrome: A Case Report.

JBJS case connector·2020
Same author

Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients.

Journal of bone and mineral metabolism·2020
Same author

The small compound, TD-198946, protects against intervertebral degeneration by enhancing glycosaminoglycan synthesis in nucleus pulposus cells.

Scientific reports·2020
Same author

Predictive factors of the 30-day mortality after surgery for spinal metastasis: Analysis of a nationwide database.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2020
Same author

In vivo length change of ligaments of normal knees during dynamic high flexion.

BMC musculoskeletal disorders·2020
Same author

Surgical margin for phosphaturic mesenchymal tumors in soft tissues: An analysis of the radiological histopathological correlation.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2020

Related Experiment Video

Updated: Mar 30, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

[Anti-RANKL antibody].

Toshinobu Omiya, Sakae Tanaka

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |November 5, 2015
    PubMed
    Summary

    Denosumab, a RANKL inhibitor, is effective for postmenopausal osteoporosis. It also shows potential in increasing bone density for rheumatoid arthritis patients, though its impact on disease activity requires further study.

    Area of Science:

    • Biochemistry
    • Immunology
    • Orthopedics

    Context:

    • The RANKL-RANK signaling pathway is crucial for osteoclast function and bone metabolism.
    • Hyperactivation of this pathway contributes to osteoporosis.
    • Denosumab is a targeted therapy developed to inhibit this pathway.

    Purpose:

    • To review the clinical utility of denosumab in managing bone density.
    • To assess the current understanding of denosumab's effects in osteoporosis and rheumatoid arthritis.

    Summary:

    • Denosumab is a monoclonal antibody that blocks receptor activator of nuclear factor-κB ligand (RANKL), thereby inhibiting osteoclast-mediated bone resorption.
    • Clinical evidence supports denosumab's efficacy in treating postmenopausal osteoporosis.
    • Studies indicate denosumab can improve bone mineral density in rheumatoid arthritis patients, particularly in the lumbar spine and proximal femur.

    More Related Videos

    A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
    09:37

    A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

    Published on: March 15, 2018

    14.9K
    Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
    08:53

    Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

    Published on: January 1, 2017

    9.9K

    Related Experiment Videos

    Last Updated: Mar 30, 2026

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
    07:42

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

    Published on: September 19, 2018

    8.4K
    A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
    09:37

    A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

    Published on: March 15, 2018

    14.9K
    Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
    08:53

    Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

    Published on: January 1, 2017

    9.9K

    Impact:

    • Denosumab offers a therapeutic option for osteoporosis by modulating bone remodeling.
    • Further research is needed to clarify denosumab's role in managing rheumatoid arthritis disease activity.
    • Understanding denosumab's effects contributes to the broader field of bone metabolism and inflammatory disease treatment.